This morning, Politico spotlighted CAHC’s MVP Act writing:
Clinical trials for cell and gene therapies are surging, according to the latest data from the Alliance for Regenerative Medicine, Ben reports.
About 1,000 trials were conducted in 2018, but this year, there are more than 1,600, the organization said, reflecting growing investment in the sector. The FDA could approve up to nine such therapies this year, which would be an all-time high.
View from Congress: The growth comes as Congress weighs allowing the expansion of value-based purchasing agreements between states and drugmakers through the MVP Act, which the industry has backed. Critics have charged it could become a loophole for pharma to pay lower rebates to states.
The legislation’s path forward is unclear, with Democrats divided over the bill. Just three Democrats supported it in a House Energy and Commerce Committee markup in May.